Shares of cruise lines jump after CDC ends Covid-19 program

Shares of cruise lines jump after CDC ends Covid-19 program


NEW YORK, US – JULY 10: An aerial view of the cruise ship “Norwegian Joy” sails up the Hudson River in front of the skyline of Manhattan as the sun sets in New York City, United States on July 10, 2022.

Lokman Vural Elibol | Anadolu Agency | Getty Images

Shares of cruise lines including Carnival, Royal Caribbean and Norwegian rose Tuesday after the U.S. Center for Disease Control ended its Covid-19 program for cruise ships.

The CDC’s program for cruise ships, which became voluntary earlier this year, required all passengers to be tested, encouraged vaccinations for staff and passengers and outlined specific quarantine procedures in the event of an outbreak.

The CDC said it would still provide guidance for cruise ships handling of Covid-19 cases, but that companies can now use their own strategies to mitigate the spread on the virus. That means cruise lines can make their own policies regarding vaccination, testing, and quarantine requirements.

Carnival shares gained about 7% on Tuesday to close at $10.36, while Royal Caribbean shares gained almost 6% to $36.36 and Norwegian shares rose roughly 3.5% to $12.85.

The CDC’s change is expected to give cruise liners more flexibility, which could allow for more travelers on ships and lower costs for the industry.

“While we fully expect the cruise operators to continue to mandate passengers to be vaccinated before sailing,” wrote Steven M. Wieczynski, a Stifel analyst. “We believe today’s news will give the cruise operators more flexibility around the inclusion of younger individuals.”

A Royal Caribbean representative said the company is awaiting further guidance from the CDC before setting its own policies.

The cruise industry has been reeling since the pandemic began, and has more recently been working to recover business back toward pre-2020 levels.



Source

We’re buying the dip in a health and life sciences stock that has gone down enough
Health

We’re buying the dip in a health and life sciences stock that has gone down enough

We’re buying 20 more shares of Danaher at roughly $180 each. Following Thursday’s trade, Jim Cramer’s Charitable Trust will own 470 shares of DHR, increasing its weighting to about 2.31% from about 2.22%. While Danaher has certainly been one of a handful of problematic stocks in the portfolio, we are stepping into the name here, […]

Read More
Roche targets becoming top 3 obesity player as experimental drug enters late-stage trial
Health

Roche targets becoming top 3 obesity player as experimental drug enters late-stage trial

The Roche Holding AG headquarters on April 11, 2025, in Basel, Switzerland. Sedat Suna | Getty Images News | Getty Images Swiss pharmaceutical firm Roche is targeting becoming a top three obesity player globally, posing a potential rival to heavyweights Novo Nordisk and Eli Lilly as it advances one of its experimental weight-loss drugs to […]

Read More
Eli Lilly to build .5 billion Texas manufacturing facility for obesity pill, other drugs
Health

Eli Lilly to build $6.5 billion Texas manufacturing facility for obesity pill, other drugs

A rendering of Eli Lilly’s manufacturing facility in Houston, Texas. Courtesy: Eli Lilly Eli Lilly on Tuesday said it will spend $6.5 billion to build a manufacturing facility in Houston, Texas, to boost production of the company’s pipeline of so-called small molecule drugs, including its closely watched experimental obesity pill.  It is the second in […]

Read More